JNJ

188.32

+0.35%↑

ABT

123.92

-0.98%↓

TMO

564.13

+1.23%↑

ISRG

536.68

+0.42%↑

DHR

217.08

+1.46%↑

JNJ

188.32

+0.35%↑

ABT

123.92

-0.98%↓

TMO

564.13

+1.23%↑

ISRG

536.68

+0.42%↑

DHR

217.08

+1.46%↑

JNJ

188.32

+0.35%↑

ABT

123.92

-0.98%↓

TMO

564.13

+1.23%↑

ISRG

536.68

+0.42%↑

DHR

217.08

+1.46%↑

JNJ

188.32

+0.35%↑

ABT

123.92

-0.98%↓

TMO

564.13

+1.23%↑

ISRG

536.68

+0.42%↑

DHR

217.08

+1.46%↑

JNJ

188.32

+0.35%↑

ABT

123.92

-0.98%↓

TMO

564.13

+1.23%↑

ISRG

536.68

+0.42%↑

DHR

217.08

+1.46%↑

Search

Ionis Pharmaceuticals Inc

Abierto

SectorSalud

73.96 2.06

Resumen

Variación precio

24h

Actual

Mínimo

73.06

Máximo

74.74

Métricas clave

By Trading Economics

Ingresos

270M

124M

Ventas

320M

452M

Margen de beneficio

27.331

Empleados

1,069

EBITDA

294M

150M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+12.41% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

5.1B

12B

Apertura anterior

71.9

Cierre anterior

73.96

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 oct 2025, 23:32 UTC

Acciones populares

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 oct 2025, 23:02 UTC

Ganancias

AIA Group 3Q Value of New Business Grew

30 oct 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 oct 2025, 23:00 UTC

Ganancias

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 oct 2025, 22:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

30 oct 2025, 22:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 oct 2025, 22:56 UTC

Charlas de Mercado

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 oct 2025, 22:35 UTC

Ganancias

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 oct 2025, 22:35 UTC

Ganancias

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 oct 2025, 22:31 UTC

Ganancias

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 oct 2025, 22:29 UTC

Ganancias

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q EPS 66c >BVN

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q Rev $431M >BVN

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q Net $179M >BVN

30 oct 2025, 22:16 UTC

Charlas de Mercado
Ganancias

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 oct 2025, 22:14 UTC

Ganancias

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 oct 2025, 22:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 oct 2025, 21:39 UTC

Ganancias

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct 2025, 21:26 UTC

Ganancias

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct 2025, 21:14 UTC

Charlas de Mercado
Ganancias

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

30 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 oct 2025, 21:04 UTC

Ganancias

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 oct 2025, 21:03 UTC

Ganancias

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 oct 2025, 21:03 UTC

Ganancias

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold Skouries on Track for 1Q of 2026

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Adj EPS 41c >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Rev $434.7M >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Net $56M >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q EPS 27c >EGO

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

12.41% repunte

Estimación a 12 meses

Media 80.8 USD  12.41%

Máximo 100 USD

Mínimo 46 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

17

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

168 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat